Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based studySatveer K. Mahil, Anthony Bewley, Esther A. Balogh et al.|Journal of Allergy and Clinical Immunology|2020Cited by 160
Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre StudyTiago Torres, Paolo Gisondi, Andrea Chiricozzi et al.|American Journal of Clinical Dermatology|2024Cited by 58
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Antonio Costanzo, Alessandra Narcisi et al.|Frontiers in Medicine|2023Cited by 55
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational studyMarina Talamonti, Marco Galluzzo, Andrea Chiricozzi et al.|Expert Opinion on Biological Therapy|2020Cited by 43
Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis)Diego Orsini, Antonio Costanzo, Piergiorgio Malagoli et al.|Dermatology Practical & Conceptual|2024Cited by 34